ÐÂÎÅ×ÊѶ
Cell·¢ÎĽÒʾйڷÎÑײ¡È˵ÄѪҺµ°°××éÌØÕ÷
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÈðÈð
- À´Ô´£ºk8¿·¢(Öйú)¹«ÖÚºÅ
¡¾¸ÅÒªÃèÊö¡¿ÔõÑù²ÅÄÜÈ«ÃæµÄ¶ÔѪҺµ°°××é½øÐмì²â£¬É¸Ñ¡ÖØÒªµÄDZÔÚ±êÖ¾ÎïÄØ£¿½ñÌìk8¿·¢(Öйú)¾ÍÒÔ½üÆÚ·¢±íµÄһƪÏà¹ØÎÄÕÂΪÀý£¬·ÖÏíѪҺµ°°×±êÖ¾ÎïµÄÓÅÑ¡½â¾ö·½°¸£¬ÒÔ÷϶ÁÕߣ¡
Cell·¢ÎĽÒʾйڷÎÑײ¡È˵ÄѪҺµ°°××éÌØÕ÷
¡¾¸ÅÒªÃèÊö¡¿ÔõÑù²ÅÄÜÈ«ÃæµÄ¶ÔѪҺµ°°××é½øÐмì²â£¬É¸Ñ¡ÖØÒªµÄDZÔÚ±êÖ¾ÎïÄØ£¿½ñÌìk8¿·¢(Öйú)¾ÍÒÔ½üÆÚ·¢±íµÄһƪÏà¹ØÎÄÕÂΪÀý£¬·ÖÏíѪҺµ°°×±êÖ¾ÎïµÄÓÅÑ¡½â¾ö·½°¸£¬ÒÔ÷϶ÁÕߣ¡
- ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
- ×÷ÕߣºÈðÈð
- À´Ô´£ºk8¿·¢(Öйú)¹«ÖÚºÅ
- ·¢²¼Ê±¼ä£º2022-03-16 10:11
- ·ÃÎÊÁ¿£º
Ѫ½¬µ°°×µÄŨ¶È¿ç¶È·¶Î§¼°Æä¹ã£¬´Ó¸ß·á¶È°×µ°°×¡¢ÃâÒßÇòµ°°×µÈµÄmg/ml£¬µ½°×½éËØ¡¢¸ÉÈÅËصÈϸ°ûÒò×ÓµÄpg/ml£¬ºÜÄÑÓõ¥Ò»µÄ¼¼Êõ¿ÉÒÔ½«ÕâЩµ°°×¶¼ÄÜͬʱ¼ì²âµ½£¬ÌرðÊÇ¿¼Âǵ½µÍ·á¶Èµ°°×µÄ¼ø¶¨ºÍ¼ì²â£¨Í¼1£©¡£
ÔõÑù²ÅÄÜÈ«ÃæµÄ¶ÔѪҺµ°°××é½øÐмì²â£¬É¸Ñ¡ÖØÒªµÄDZÔÚ±êÖ¾ÎïÄØ£¿½ñÌìk8¿·¢(Öйú)¾ÍÒÔ½üÆÚ·¢±íµÄһƪÏà¹ØÎÄÕÂΪÀý£¬·ÖÏíѪҺµ°°×±êÖ¾ÎïµÄÓÅÑ¡½â¾ö·½°¸£¬ÒÔ÷϶ÁÕߣ¡
ͼ1 Ѫ½¬µ°°×Ũ¶È·¶Î§(Schiess et al. Mol Oncol. 2009)
½üÆÚCellÔÓÖ¾·¢±íÁËÒ»ÏîÌâΪ“A blood atlas of COVID-19 defines hallmarks of disease severity and specificity”µÄÑо¿1£¬¸ÃÑо¿ÀûÓöà×éѧ¼¼ÊõÚ¹ÊÍÁËCOVID-19µÄÍâÖÜѪÌØÕ÷¡£¸ÃÑо¿ÄÉÈëÁË100¶àÃûסԺµÄCOVID-19»¼Õߣ¬ÒÔ¼°¿µ¸´ÆÚµÄÉçÇøCOVID-19²¡ÈË£¬½¡¿µÕߣ¬ÖØÖ¢µÄÁ÷¸Ð»¼ÕߺÍŧ¶¾Ö¢»¼Õß¡£ÆäÖÐסԺµÄCOVID-19²¡ÈËÒÀ¾ÝWHOµÄ·ÖÀà±ê×¼·ÖΪÁËÖжȡ¢Öضȡ¢Î£ÖضÈÈý¸ö³Ì¶È¡£Ñо¿ÕßÀûÓÃÖÊÆ×Á÷ʽ£¨CyTOF£©¡¢CITE²âÐò¡¢×ªÂ¼×é²âÐò¡¢µ¥Ï¸°û²âÐò¡¢BCRºÍTCR²âÐò¡¢4Dµ°°××éTimsTOFÖÊÆ×¼¼ÊõºÍLuminexϸ°ûÒò×Ó¼ì²â¼¼Êõ·ÖÎöÁËCOVID-19²¡ÈËÍâÖÜѪÌØÓеÄϸ°û×é³ÉºÍ·Ö×ÓÌØÕ÷£¬Í¨¹ýWGCNA·ÖÎö¡¢»úÆ÷ѧϰ½øÐÐÌØÕ÷±äÁ¿Ñ¡ÔñµÈËã·¨ÒÔ¼°¶à×éѧÕûºÏ·ÖÎö·½·¨¼ø¶¨ÁËÓëCOVID-19¼²²¡ÑÏÖس̶ÈÃÜÇÐÏà¹ØµÄÃâÒßϸ°ûÑÇȺ¡¢¹Ø¼üµÄ»ùÒòºÍµ°°×ÒÔ¼°ÖØÒªµÄÉúÎïѧ¹ý³ÌºÍͨ·£¬ÎªCOVID-19¼²²¡µÄ¾«×¼ÖÎÁÆÌṩÁËÖØÒªµÄ²Î¿¼ÒÀ¾Ý£¨Í¼2£©¡£
ͼ2 COVID-19¼²²¡µÄѪҺ¶à×éѧÑо¿
ÕâÏîÑо¿ÀûÓÃÁËÖÊÆ×¼¼ÊõºÍ¿¹ÌåоƬ¼¼Êõ¿ªÕ¹ÑªÇå/½¬µ°°××éѧµÄ·ÖÎö¡£Ñо¿ÕßÊ×ÏÈͨ¹ý4Dµ°°××éƽ̨TimsTOF ProÖÊÆ×ÒÇ (Bruker Daltonics)·ÖÎöÁËÀ´×Ô257¸öÊÜÊÔÕß×ܹ²340·ÝѪ½¬Ñù±¾¡£ÖÊÆ×½á¹û±íÃ÷Ѫ½¬µ°°××é¿ÉÒÔÒÀ¾Ý¼²²¡µÄÑÏÖس̶Ƚ«Ñù±¾·Ö¿ª£¨Í¼3A£©£¬¼²²¡µÄÑÏÖØÐÔÓë¼±Ïà·´Ó¦µ°°×¡¢²¹Ìåϵͳµ°°×ÃÜÇÐÏà¹Ø£¬ÀýÈçSAA1, SAA2, CRP, C5, C6, C9, CFB, SERPINA3, SERPINA1, ITIH3, APCµÈµ°°×£¨Í¼3B£©¡£µ°°×»¥×÷ÍøÂç·ÖÎöչʾÁ˲ÎÓ뵨¹Ì´¼×ªÔË£¨cholesterol transport£©ºÍ ÏËάµ°°×ѪÄý(fibrin blood clots)µÄ³ÉÔ±·Ö±ðÐγÉÁË2¸ö×î´óµÄµ°°×´Ø£¨Í¼3C£©¡£ËµÃ÷ÁËÕâЩÉúÎïѧ¹ý³ÌÓëCOVID-19¼²²¡µÄÑÏÖس̶ȷdz£Ïà¹Ø¡£Ö®ºóÑо¿ÕßÀûÓÃLuminex¼¼Êõ¼ì²âÁËѪÇå/½¬ÖÐ51¸öϸ°ûÒò×ÓºÍÇ÷»¯Òò×Ó¡£½á¹û±íÃ÷ÁË25¸öÒò×ÓÔÚCOVID-19²¡È˺ͽ¡¿µÈ˼ä´æÔÚÏÔÖøÐÔ²îÒ죬ÆäÖÐCCL2, CCL19, CCL20, CXCL10, GM-CSF, IL-6, IL-8, IL-15, S100A9, SCGFÓëסԺCOVID-19²¡È˵ÄÑÏÖس̶ȸ߶ÈÏà¹Ø£¨Í¼3D£©¡£½øÒ»²½µÄµ°°×ºÍÁÙ´²Ö¸±êÏà¹ØÐÔÍøÂç·ÖÎöչʾÁ˼¸¸öÁÙ´²ÌØÕ÷ÓëÍøÂçÖÐÐĵĽڵ㵰°×³ÊÏÖºÜÇ¿µÄÏà¹ØÐÔ£¬°üÀ¨GM-CSF, CXCL10, TREM-1, CCL2/19, TF, IL-6/15, MPO, S100A9µ°°×£¨Í¼3E£©¡£
ͼ3 4DÖÊÆ׺ÍоƬ¼¼Êõ·ÖÎöѪ½¬µ°°××é
Ñо¿ÕßÓÖÀûÓÃÏàËÆÍøÂçÈںϵķ½·¨£¨Similarity Network Fusion, SNF£©ÕûºÏÖÊÆ×Êý¾ÝºÍоƬÊý¾Ý¶ÔסԺCOVID-19²¡È˽øÐÐÑÇÐÍ·ÖÀࣨͼ4A£©¡£½á¹ûºÜÃ÷ÏÔ¿ÉÒÔ½«²¡ÈË·ÖΪÁ½¸öÑÇȺ£¬²¢ÇÒÕâÁ½¸öÑÇȺҲ¿ÉÒÔͨ¹ýÁÙ´²Ö¸±êÇø·Ö£¨Í¼4B£©£¬ÀýÈçÎüÑõŨ¶ÈºÍSOFA·ÖÊý£¬ÑÇȺ1¼²²¡ÑÏÖس̶ȵͣ¬ÑÇȺ2¼²²¡ÑÏÖس̶ȸߣ¨Í¼4C£©¡£ÓëÖ®Ò»Öµģ¬ÕâÁ½¸öÑÇȺµÄ²¡ÈËÓë28ÌìËÀÍöÂÊÃÜÇÐÏà¹Ø£¬ÑÇȺ1Óе͵ÄËÀÍöÂÊ£¬¶øÑÇȺ2ÓиßËÀÍöÂÊ£¨Í¼4D£©¡£ÕâЩ½á¹û˵Ã÷ÁËѪÇå/½¬µ°°××é¿ÉÒÔ×÷ΪCOVID-19²¡ÈËÔ¤ºóµÄ±êÖ¾Îï¡£×îºóÑо¿Õß¼ø±ðÁËÇø·ÖÁ½¸öÑÇȺ×îÖ÷ÒªµÄ11¸öµ°°×£¬°üÀ¨IL-6, IL-8, CCL2, CCL19, CCL20, CXCL10, S100A9, SAA1, SERPINA3, GM-CSF, CLEC11A¡£
k8¿·¢(Öйú)½«ÖÊÆ×¼¼ÊõºÍ¿¹ÌåоƬ¼¼ÊõÓлú×éºÏ£¬ÊµÏÖѪҺ±êÖ¾ÎïµÄÈ«·½Î»µÄ¼ì²â£¡
ͼ4 »ùÓÚѪ½¬µ°°××éµÄ¼²²¡·ÖÐÍ
Ñо¿ÕßÓÖ½øÐÐÁ˶à×éѧµÄÕûºÏ·ÖÎö£¬Í¨¹ý»úÆ÷ѧϰËã·¨¼ø¶¨ÁËÔ¤²â¼²²¡ÑÏÖس̶ȵÄDZÔÚ±êÖ¾Î·¢ÏÖÁ˾ßÓиßЧÄܵÄÔ¤²â±êÖ¾Îï×éºÏ£¬°üÀ¨SAA2, CRP, IGHG4, CL20, CCL2, IL-6ºÍC5aµ°°×£¨Í¼5A,B£©¡£Ñо¿Õß×îºóÀûÓÃÕóÁÐÏ¡Êè·Ö½â£¨SDA£©Ëã·¨·¢ÏÖÁ˺ܶàÓë¼²²¡ÑÏÖس̶ÈÏà¹ØµÄÄ£¿é£¬ÕâЩģ¿éÓɲ»Í¬µÄϸ°ûÑÇȺ¡¢»ùÒòºÍµ°°××é³É£¨Í¼5C£©¡£ÀýÈçÆäÖÐÒ»¸öÓëCOVID-19¼²²¡ÑÏÖس̶È×îÏà¹ØÄ£¿ì×é³É°üÀ¨Ôö¼ÓµÄѪ½¬Ç÷»¯Òò×ÓCXCL8, CXCL10, CCL20ºÍGM-CSF£¬¼°¼±Ïà·´Ó¦µ°°×SAA1/2, SERPINA3, LRG1 ºÍLBP; ¼õÉÙµÄÖм䵥ºËϸ°û; ¸ß±í´ïµÄ·Ö×Ó°éÂÂCLU»ùÒòºÍ¼×»ùתÒÆøMETTL7B»ùÒò£»Ïµ÷µÄlgEÊÜÌå»ùÒòºÍ¶à¸öHLA-II»ùÒò£»Ó뿹Գʵݡ¢TCRÐźźÍÏø´Ïà¹ØµÄ¸»¼¯Í¨Â·µÈ£¨Í¼5D£©¡£×îºó»¹¼ø±ðÁËÏà¶ÔÓÚŧ¶¾Ö¢ºÍÁ÷¸Ð¼²²¡£¬COVID-19Ïà¹ØµÄһЩÌØÓеÄÄ£¿é£¬×ÜÖ®ÕâЩ½á¹û˵Ã÷ÁËͨ¹ýµ°°××顢ת¼×é¡¢µ¥Ï¸°ûµÈ¶à×éѧ·ÖÎö¿ÉÒÔ¼ø¶¨COVID-19¼²²¡ÑÏÖس̶ȺÍÌØÒìµÄÏà¹ØѪҺÌØÕ÷£¬ÎªÀí½âCOVID-19¼²²¡µÄ²¡Àí»úÖÆ£¬¼ø¶¨Õï¶ÏºÍÔ¤²â±êÖ¾Îï¼°¾«×¼ÖÎÁÆÌṩÖØÒªÒÀ¾Ý¡£
| ×ܽáÓë½áÂÛ
Ä¿Ç°³£ÓõÄÁ½ÖÖѪ½¬µ°°×¼ì²â¼¼ÊõÊÇÖÊÆ×¼¼ÊõºÍ»ùÓÚ¿¹ÌåµÄ¼ì²â¼¼Êõ¡£¶ÔÓÚÖÊÆ×¼¼Êõ£¬Ñª½¬¸ß·á¶Èµ°°×»áÑڸǺ͸ÉÈŵͷá¶Èµ°°×µÄ¹Û²ì¡£µ«ÊǶàÖÖÑù±¾Ô¤´¦Àí·½·¨µÄÓ¦Óü°ÖÊÆ×¼¼ÊõµÄÉý¼¶¿ÉÒÔÔÚÒ»¶¨³Ì¶ÈÉϽâ¾öÉÏÊöÎÊÌâ¡£ÀýÈçÖÊÆ×¼ì²âÇ°Ô¤ÏÈÈ¥³ýѪ½¬10¶àÖָ߷á¶Èµ°°×£¬²ÉÓÃÊý¾Ý·ÇÒÀÀµµÄ²É¼¯Ä£Ê½£¨DIA£©ÊµÏÖëĶÎÈ«·¶Î§µÄɨÃ裬ÌرðÊÇ°éËæ×Å4Dµ°°××éʱ´úµÄµ½À´£¬ÖÊÆ׵ļì²âÁéÃô¶È¡¢×¼È·¶ÈºÍ¸²¸ÇÉî¶ÈµÃµ½ÁË¿çʱ´úµÄÌáÉý¡£ÕâЩ¸ß¾«¶ÈµÄÖÊÆ×¼¼ÊõÒѾÖð½¥³ÉΪѪ½¬±êÖ¾Îï·¢Ïֺͼø¶¨µÄÖØÒªÊֶΡ£»ùÓÚ¿¹ÌåµÄ¼ì²â¼¼Êõ°üÀ¨¸÷ÖÖ¹ÌÏ࿹ÌåоƬ¼°LuminexÒºÏàÐü¸¡Ð¾Æ¬µÈ£¬ÕâЩоƬÒÀÀµÓÚʹÓõĿ¹Ì壬¿ÉÒÔ¼ì²âÄÇЩµÍ·á¶ÈµÄµ°°×£¬¶øÎÞÐèÈ¥³ý¸ß·á¶Èµ°°×£¬ÌرðÊÊÓÃÓÚ¼ì²âѪҺÖк¬Á¿Ïà¶ÔµÍµÄÑ×Ö¢Òò×Ó¡¢Éú³¤Òò×Ó¡¢Ç÷»¯Òò×ÓºÍÉñ¾Òò×ӵȡ£ÖÊÆ׺Ϳ¹ÌåоƬÁ½ÖÖ¼¼Êõ¿ÉÒÔÓÅÊÆ»¥²¹£¬Á½Õß½áºÏÎÞÒÉ¿ÉÒԷḻ¼ø¶¨µÄµ°°×ÊýÁ¿£¬·¢ÏÖ¸ü¶àDZÔڵıêÖ¾Îï¡£
k8¿·¢(Öйú)Ò»Ö±ÖÂÁ¦ÓÚѪҺµ°°×±êÖ¾ÎïµÄÑо¿ºÍ·þÎñ£¬Æ¾½è¶àÄê¾Ñé¼°ÏȽøµÄ¼ì²âƽ̨¿ÉÒÔΪ´ó¼ÒÌṩϵͳ»¯µÄѪҺ±êÖ¾Îï½â¾ö·½°¸¡£¾Íµ°°××é¶øÑÔ£¬³ýÁ˳£¹æµÄ¼¼Êõ£¬»ªÓ¯»¹ÓµÓÐÄ¿Ç°×îÏȽøµÄ4D-DIAÖÊÆ×¼ì²âƽ̨£¬²¢ÇÒÊÇ4Dµ°°××é“˫ƽ̨”£¬¿ÉÂú×㲻ͬÑо¿µÄÐèÇ󡣶ÔÓÚѪҺµÍ·á¶ÈµÄϸ°ûÒò×Ó£¬»ªÓ¯ÓµÓГ¸ßͨÁ¿¿¹ÌåоƬ”¡¢“LuminexÒºÏàÐü¸¡Ð¾Æ¬”¡¢“µ¥·Ö×Ó¸ßÃôSimoa¼¼Êõ”Èý¸öϸ°ûÒò×Ó¼ì²âƽ̨£¬¿ÉÒÔͬ²½¼ì²â¼¸Ê®ÖÁ¼¸Ç§¸öÒò×Ó£¬¼ì²âÁéÃô¶È¿ÉÒÔ´ïµ½fg¼¶£¨Simoa£©¡£
k8¿·¢(Öйú)½«ÖÊÆ×¼¼ÊõºÍ¿¹ÌåоƬ¼¼ÊõÓлú×éºÏ£¬ÊµÏÖѪҺ±êÖ¾ÎïµÄÈ«·½Î»µÄ¼ì²â£¡
| ²Î¿¼ÎÄÏ×
1.COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. 2022. In Press.
µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã
µç»°£º400-869-2936£¬021-33968791
ÓÊÏ䣺support@wayenbiotech.com
´«Õ棺021-33938792
QQ£º2120485725
Õ½ÂÔºÏ×÷
Õ½ÂÔºÏ×÷
| Full Moon | RayBiotech | CDI | IZON | Bio-Rad | R&D Systems | IsoPlexis | ÄÏÄ£ÉúÎï | Å·Ò×ÉúÎï | ÆäÃ÷ÐÅÏ¢ | ÃÀ¼ªÉúÎï | ÂóÌØ»æÆ× |
Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿·¢(Öйú)Ô´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£